3Swigris J J, Han M, Vii R, et al. The UCSD Shortness of Breath Questionnaire has longitudinal construct validity in id- iopathic pulmonary fibrosis [J ]. Respir Med 2012, 106: 1447.
4Patel A S, Siegert R J, Brignall K, et al. The development and validation of the King' s Brief Interstitial Lung Disease (K-BILD) health status questionnaire[J]. Thorax, 2012, 67 : 804.
5Winklehner A, Berger N, Maurer B, et al. Screening for in terstitial lung disease in systemic sclerosis: the diagnostic ac curacy of HRCT image series with high increment and re duced number of slices[J]. Ann Rheum Dis, 2012, 71 549.
7Wells A U, Behr J, Costabel U, et al. European IPF Con- sensus Group. Hot of the breath: mortality as a primary end - point in IPF treatment trials: the best is the enemy of the gcod[J]. Thorax 2012, 67: 938.
8Corte T J, Goh N S, Glaspole I N, et al. Idiopathic pul- monary fibrosis: is all - cause mortality a practical and realis- tic end-point for clinical trials[J]. Thorax 2013, 68: 491.
9何楠.30例结缔组织病合并肺间质病变临床分析[J].中国实用医学,2014,56(3):32.
10Bajwah S, RossJ R, Peacock J L, et al. Interventions to im- prove symptoms and quality of life of patients with fibrotic in- terstitial lung disease: a systematic review of the literature EJ]. Thorax, 2013, 68: 867.
